COMMUNIQUÉS West-GlobeNewswire

Veru to Present Two Abstracts at ObesityWeek 2025
31/10/2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
NewGen Enters Into an Innovative Digital Assets Purchase Agreement with White Lion to Acquire up to 600,000 Solana Tokens Valued at Over $110 Million
31/10/2025
BANGKOK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through [...]
Disc Medicine to Participate in Upcoming Investor Conferences
31/10/2025
WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
31/10/2025
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
Prenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR
31/10/2025
Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity Offering Company now holds a total of 378 BTC (valued at ~$41 Million) CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited [...]
IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies
31/10/2025
DAEJEON, South Korea and NORTH BETHESDA, Md., Oct. 31, 2025 (GLOBE NEWSWIRE) -- IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for antibody–drug [...]
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
31/10/2025
Faster initial remission and response, persistent benefit over six months SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision [...]
Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
31/10/2025
Correcting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline. COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage [...]
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
31/10/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
31/10/2025
Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome [...]
PharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in Egypt
31/10/2025
GOLDEN, Colo. and CAIRO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- PharmaJet ® , a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced [...]
Test And Tren Cycle For Muscle Growth - CrazyBulk Lunch Test and Tren Stack (Tren Max) Pills for Bodybuilding, Beginners Dosage, Benefits, Before And After Results
31/10/2025
CrazyBulk Introduce Test and Tren Stack for Bodybuilding, legal Steroids Alternative Pills for Test and Tren Cycle Read Dosage For Beginners, and (Tren Max) Pills Before And After Results NEW YORK, Oct. 31, 2025 (GLOBE [...]
Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy
31/10/2025
CHICAGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the initiation of a new [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
31/10/2025
COPENHAGEN, Denmark, October 31, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.99% [...]
Immuron Announces Clinical Trial Update
31/10/2025
IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan ® P2TD (n=851) Uniformed Services University study topline data delayed to the end [...]
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
31/10/2025
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the IL-4 and IL-13 [...]
BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers
31/10/2025
Randomized controlled trial results published in the International Journal of Tissue Repair demonstrate BioRetain® allografts significantly improve probability of achieving lasting wound closure versus standard of care [...]
Upstream Bio to Participate in Upcoming November Investor Conferences
31/10/2025
WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
31/10/2025
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with [...]

Pages